[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"progressive-multiple-sclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:progressive-multiple-sclerosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,50,73,100,126,151,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100568027","phase-1-open-label-multi-center-phase-iii-study-to-assess-safety-disease-progression-and-cellular-kinetics-following-ytb323-administration-in-participants-with-non-active-progressive-multiple-sclerosis-pms-100568027",false,"NCT06675864","Open-label, Multi-center, Phase I\u002FII Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)","An Open-label, Multi-center, Phase I\u002FII Study to Assess Safety, Disease Progression, and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)","Key Inclusion Criteria:\n\n1. Male or female participants 18 to 60 years (inclusive) at screening.\n2. Signed informed consent must be obtained prior to participation in the study.\n3. Able to communicate well with the investigator, to understand and comply with the requirements of the study including:\n\n   * Able to undergo lumbar puncture (LP), blood draws, tolerate brain and spinal MRI, and able to participate and tolerate all study procedures at study visits.\n4. Diagnosis of SPMS or PPMS according to the 2017 McDonald diagnostic criteria (Thompson et al 2018) as confirmed at screening visit.\n5. Less than 15 years (inclusive) from onset of first MS symptoms as determined by the investigator during screening.\n6. Ambulatory Patients (EDSS 3 to 6.5 inclusive) at screening.\n7. Evidence of recent (within 24 months) disease progression of ≥1.00 on the EDSS scale.\n8. No relapse in the last 24 months at screening.\n9. No Gd-enhancing lesion on brain or spinal cord MRI at screening.\n10. Participants must receive or be current on all recommended vaccinations according to institutional, local, or global guidelines for immunocompromised patients at least 6 weeks prior to lymphodepletion.\n\nKey Exclusion Criteria:\n\n1. Diagnosis of relapsing multiple sclerosis (RMS) or active PMS according to the 2017 revision of the McDonald diagnostic criteria (Thompson et al 2018) at screening.\n2. History of, or current, clinically significant CNS disease except MS (e.g. stroke, traumatic brain or spinal injury, history or presence of myelopathy, history of seizures or epilepsy) or neurological disorders which may mimic MS at screening.\n3. Evidence of clinically significant cardiovascular (such as but not limited to myocardial infarction, unstable ischemic heart disease, New York Heart Association Class III\u002FIV left ventricular failure, arrhythmia and uncontrolled hypertension within 6 months prior to or during screening).\n4. Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or neurological symptoms consistent with PML prior to or during screening.\n5. Clinically significant, active, opportunistic, chronic or recurrent infection (including positive for hepatitis B or hepatitis C) confirmed by clinical evidence, imaging, or positive laboratory tests one month prior to leukapheresis.\n6. Have donated blood or experienced a loss of blood \\> 400 mL within 3 months prior screening, or longer if required by local regulations.\n7. Any prior stem cell therapy or organ transplantation or gene therapy.\n8. Any contraindications to LP, including but not limited to:\n\n   * Known or suspected structural abnormality of the lumbar spine that, in the opinion of the Investigator, may interfere with the performance of the LP, or increase the risk of the procedure for the participant.\n   * Presence of risk for increased or uncontrolled bleeding (including but not limited to vascular abnormalities or neoplasms at or near the LP site, disorders of the coagulation cascade, platelet function, or platelet count).\n   * Participants on anticoagulants (e.g., warfarin) or antiplatelets \\[except for low-dose aspirin (100 mg\u002Fday or lower) and low-dose nonsteroidal anti-inflammatory drugs such as ibuprofen (600 mg\u002Fday or lower) which are allowed\\], are not eligible to participate.\n9. Not willing or able to have MRI scans as per protocol e.g. due to claustrophobia, or absolute contraindications to MRI (e.g., metallic implants, metallic foreign bodies, pacemaker, defibrillator).\n10. Pregnant or nursing (lactating) women.\n11. Past surgical history of splenectomy.\n12. Evidence of active or latent tuberculosis (TB) infection by QuantiFERON® TB-Gold assay (or equivalent) performed at Screening by central lab. In case of unclear or indeterminate test results, the Investigator should consult with an infectious disease expert to exclude the diagnosis of active or latent TB infection and document this in the source data. Participant should be excluded if they have any signs of active TB observed in available lung imaging (e.g., X-ray or HRCT).\n13. Any psychiatric, pulmonary (including, history of or active severe respiratory disease, including Chronic Obstructive Pulmonary Disease, interstitial lung disease or pulmonary fibrosis), renal, hepatic, endocrine, metabolic (e.g. severe hypoproteinemia due to nephrotic syndrome), hematological disorders or gastrointestinal disease that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant, prior to or during screening.\n14. Grade 2 or higher thromboembolic event in the past 4 weeks prior to or during Screening or evidence of disorders of coagulation or platelet function including subjects that require chronic use of anticoagulation or antiplatelet drugs (please refer to the key exclusion criteria no. 8 for the exceptions).","ALL","18 Years","60 Years",{"count":20,"type":21},28,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.",[28],"Progressive Multiple Sclerosis",[30,31,32,33,34,28,35,36],"Chimeric Antigen Receptor T cells","CAR-T","YTB323","Multiple Sclerosis","MS","PMS","rapcabtagene autoleucel","RECRUITING","2026-06-25",{"date":40,"type":41},"2026-06-30","ACTUAL",{"date":43,"type":41},"2024-12-12",{"date":45,"type":21},"2030-06-14",{"name":47,"class":48},"Novartis Pharmaceuticals","INDUSTRY",18,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100614667","phase-2-a-study-to-evaluate-the-safety-pharmacokinetics-pharmacodynamics-and-efficacy-of-ro7268489-as-add-on-therapy-to-ocrelizumab-in-participants-with-progressive-forms-of-multiple-sclerosis-ms-100614667","NCT07282574","A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)","A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis","Mintaka","Inclusion Criteria:\n\n* PMS, in accordance with the revised 2017 McDonald criteria\n* Expanded disability status scale (EDSS) at screening between 3.0 and 6.0 inclusive\n\nExclusion Criteria:\n\n* MS relapse during the 6 months preceding the randomization date\n* Lack of peripheral venous access\n* History of alcohol or other drug abuse, in the opinion of the investigator, within 5 years prior to screening\n* Inability to complete an magnetic resonance imaging (MRI)\n* Contraindications to ocrelizumab mandatory pre-medications\n* Treatment with intravenous immunoglobulin (IV Ig) or plasmapheresis within 12 weeks prior to screening",{"count":59,"type":21},360,[25],"The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.",[28],"2026-06-19",{"date":65,"type":41},"2026-06-23",{"date":67,"type":41},"2026-03-10",{"date":69,"type":21},"2030-05-30",{"name":71,"class":48},"Hoffmann-La Roche",91,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":5},"100603686","phase-1-obe-cel-in-refractory-progressive-forms-of-multiple-sclerosis-100603686","NCT07139743","Obe-cel in Refractory Progressive Forms of Multiple Sclerosis","A Single-arm, Open-label, Phase I Study to Determine the Safety, Tolerability, and Preliminary Efficacy of Obe-cel in Participants With Refractory Progressive Forms of Multiple Sclerosis","BOBCAT","Inclusion Criteria:\n\n* Willing and able to give written informed consent for participation in the study.\n* Ability and willingness to adhere to the protocol's Schedule of Activities and other requirements.\n* Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form.\n* A female participant is eligible to participate if she is not pregnant or breastfeeding.\n* Current diagnosis of PMS.\n* Must have been treated previously with 2 disease-modifying therapies.\n\nExclusion Criteria:\n\n* Any medications prohibited by the protocol.\n* Highly active multiple sclerosis.\n* Diagnosis of another autoimmune central nervous system condition.\n* Active or uncontrolled fungal, bacterial, viral infection.\n* History of malignant neoplasms unless disease-free for at least 24 months.\n* History of heart, lung, kidney, liver transplant or hematopoietic stem cell transplant.",{"count":49,"type":21},[24],"The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of participants (single-arm). The study population comprises participants with progressive forms of MS, not responsive to highly effective therapies.\n\nUpon confirmation of study eligibility, participants will receive chemotherapy (used here for lymphodepletion) over 1 to 3 days in preparation for receiving a single obe-cel infusion.\n\nParticipants will be checked closely in the 28 days following obe-cel treatment. After this, participants will be monitored to evaluate safety and efficacy up to 24 months.",[28],[86,87,88,89,90],"Multiple sclerosis","Refractory multiple sclerosis","Progressive multiple sclerosis","Obecabtagene autoleucel","Obe-cel","2026-03-20",{"date":93,"type":41},"2026-03-23",{"date":95,"type":41},"2025-08-04",{"date":97,"type":21},"2029-08-15",{"name":99,"class":48},"Autolus Limited",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":125},"100623149","bringing-the-outdoors-in-virtual-nature-walks-for-depression-in-multiple-sclerosis-ms-patients-100623149","NCT07392879","Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients","Inclusion Criteria:\n\n* Confirmed diagnosis of progressive Multiple Sclerosis (MS, primary or secondary) by a neurologist or an MS center\n* Patient-Reported Outcomes Measurement Information System (PROMIS) Depression T-scores \\>55 at baseline\n* Ability to provide informed consent and participate in VR sessions at home\n* For Some Participants (Groups 1 and 2) currently receiving antidepressant or psychotherapy treatments (Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), or psychotherapy) for the management of depression\n\nExclusion Criteria:\n\n* Severe cognitive impairments or visual deficits that may interfere with VR use, including contraindications like agoraphobia, claustrophobia, or motion sickness\n* Current participation in other clinical trials targeting depression\n* Severe psychiatric conditions that require hospitalization, or suicidal ideation, passive or active, psychosis, or active substance and alcohol abuse (score greater than 1 on CAGE (Cut down, Annoyed, Guilty, Eye-opener) Adapted to Include Drugs (CAGE-AID))\n* Another neurological or autoimmune disease per protocol\n* Participants that require vision correction, unless that vision correction is mild (± 1), or the participant has prescription contact lenses.",{"count":107,"type":21},40,[109],"NA","This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems.\n\nThe study hypotheses include:\n\n* The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions.\n* The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.",[28,112],"Depression",[114],"Immersive virtual reality (VR)","2026-02-09",{"date":117,"type":41},"2026-02-12",{"date":119,"type":41},"2025-12-15",{"date":121,"type":21},"2027-04",{"name":123,"class":124},"University of Michigan","OTHER",1,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":125},"100501573","effects-of-transcranial-static-magnetic-field-stimulation-tsms-in-progressive-multiple-sclerosis-100501573","NCT05811013","Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis","Inclusion Criteria:\n\n* Ability to give written informed consent to the study\n* Age range 18-65 years\n* Diagnosis of primary of secondary progressive MS according to 2017 revised Macdonald's criteria (Thompson et al., 2017), presenting with signs of symptoms of progressive dysfunction of the corticospinal tract\n* EDSS ≤ 6,5\n* Ability to participate to the study protocol\n* No or stable (at least six months) DMT or rehabilitative treatments before study entry, and willingness not to change these therapies (including cannabinoids, SSRI, baclofen) during the study.\n\nExclusion Criteria:\n\n* Relapsing-remitting MS or progressive MS presenting with signs of symptoms other than those typical of the ascending myelopathy phenotype (i.e. progressive cerebellar or cognitive involvement)\n* Female with positive pregnancy test at baseline or having active pregnancy plans\n* Comorbidities for which synaptic plasticity may be altered (i.e., Parkinson's disease, Alzheimer's disease, stroke)\n* Contraindications to TMS\n* History or presence of any unstable medical condition such as malignancy or infection\n* Use of medications with increased risk of seizures (i.e. Fampridine, 4-Aminopyridine)\n* Concomitant use of drugs that may alter synaptic transmission and plasticity (L-dopa, antiepileptics)","65 Years",{"count":107,"type":21},[109],"In multiple sclerosis (MS) brains, inflammation induces specific abnormalities of synaptic transmission, collectively called inflammatory synaptopathy. Such synaptopathy consists in unbalanced glutamatergic and GABAergic transmission and in remarkable changes in synaptic plasticity, causing excitotoxic neurodegeneration and impairing the clinical compensation of the ongoing brain damage, thereby exacerbating the clinical manifestation of the disease. In progressive MS (PMS), synaptopathy is characterized by pathological potentatiation of glutamate-mediated synaptic up-scaling (Centonze et al., 2008; Rossi et al., 2013) and loss of long-term synaptic potentiation \\[LTP (Weiss et al., 2014)\\], both caused by proinflammatory molecules (released by microglia, astroglia, and infiltrating T and B lymphocytes) (Malenka et al., 2004; Di Filippo et al., 2017; Stampanoni Bassi et al., 2019). The combination of increased up-scaling and decreased LTP has a significant impact on the clinical manifestations of PMS, often presenting with signs and symptoms indicating length-dependent degeneration of neurons of the corticospinal tract. Altered LTP expression impairs brain ability to compensate ongoing neuronal loss (Stampanoni Bassi et al., 2020), and pathological TNF-mediated up-scaling may directly promote excitotoxic damage and neurodegeneration (Rossi et al., 2014). In addition, up-scaling and LTP are mutually exclusive at a given synapse through a mechanism of synaptic occlusion (i.e., pre-existing up-scaling saturates and prevents subsequent LTP expression), further promoting neurodegeneration by preventing the pro-survival effect of LTP, the induction of which activates intracellular anti-apoptotic pathways (Bartlett \\& Wang, 2013). It follows that a neuromodulation approach that can chronically (over several months) dampen up-scaling expression in the primary motor cortex (M1) of PMS patients could be beneficial by preventing excitotoxic neurodegenerative damage triggered by up-scaling itself (Centonze et al. 2008, Rossi et al. 2014), and also by promoting LTP induction and LTP-dependent functional compensation of deficits, thereby reducing the speed of the neurodegeneration process through increased LTP-dependent neuronal survival and preservation of dendritic spines (Ksiazek-Winiarek et al., 2015). Our study aims to test whether transcranial static magnetic field stimulation (tSMS) could represent such a therapeutic approach, as recently proposed in patients with amyotrophic lateral sclerosis (ALS) (Di Lazzaro et al, 2021). Forty (40) ambulatory patients with PMS, presenting with the ascending myelopathy phenotype of the disease, will be recruited at the MS Center of the Unit of Neurology of the IRCCS Neuromed in Pozzilli (IS). In this randomized, sham-controlled, double-blind, within-subjects, cross-over study (allocation ratio 1:1), we will test the ability of repeated sessions of tSMS applied bilaterally over the M1 to safely reduce disability progression in patients with PMS. Patients will be randomly assigned to either real or sham tSMS. Each patient will participate in two experimental phases (real or sham stimulation). Each patient will self-administer tSMS over right and left M1, two session per day, 60 minutes each. The order will be randomly established and counterbalanced across participants. Both investigators and participants will be blinded to stimulation parameters. In the \"real stimulation\" phase, tSMS will be applied for 120 minutes each day, at home, for 12 consecutive months. In the \"sham stimulation\" phase, sham tSMS will be delivered with non-magnetic metal cylinders, with the same size, weight and appearance of the magnets. Clinical evaluations, including the Multiple Sclerosis Functional Composite measure (MSFC) will be performed before, during and after each experimental phase (\"real\" and \"sham\"). In addition, blood levels of neurofilaments, excitability and plasticity of M1, and MRI measures of cortical thickness will be measured before, during and after each stimulation phase.",[28],[28,138,139,140,141],"transcranial Static Magnetic Field Stimulation","disability progression","cortical hyperexcitability","cortical plasticity","2024-10-14",{"date":144,"type":41},"2024-10-16",{"date":146,"type":41},"2023-05-27",{"date":148,"type":21},"2026-05-27",{"name":150,"class":124},"Neuromed IRCCS",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":177,"locationsCount":125},"100553363","telerehabilitation-in-progressive-multiple-sclerosis-100553363","NCT06485115","Telerehabilitation in Progressive Multiple Sclerosis","The Effectiveness of Combining a Home-based Digital Motor Telerehabilitation Program With Conventional Therapy in Progressive Multiple Sclerosis: a Multicentre, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-75;\n* Diagnosis of MS (primary or secondary progressive);\n* Mild to moderate balance impairments with increased fall risk, defined as TUG \\> 8.4s;\n* A disability rate, as calculated using the Kurtzke Expanded Disability Status Scale (EDSS) lower than 7;\n* Acceptable level of digital skills;\n* The presence of the caregiver.\n\nExclusion Criteria:\n\n* Other conditions that may affect motor function;\n* Impaired cognitive functioning (Mini-Mental Status Examination \\\u003C24\u002F30);\n* Severe visual deficits (daltonism and visual acuity deficit);\n* Unable or refused to attend the rehabilitation treatment.\n\nPatients who fulfill the following specified inclusion criteria will also undergo an EEG evaluation. However, ineligibility for this examination does not exclude them from participating in the rehabilitation study.\n\nThe inclusion criteria for the EEG protocol will include:\n\n* The absence of metallic implants in the brain;\n* No history of brain surgery;\n* No use of medications that alter cortical excitability or are presumed to affect brain plasticity;\n* Right-handed dominance.","75 Years",{"count":160,"type":21},78,[109],"Multiple sclerosis (MS) is a highly disabling chronic, inflammatory, demyelinating disease of the Central Nervous System (CNS). Significant progress has been made during the past three decades in managing the relapsing-remitting phase of Multiple Sclerosis (RRMS). However, once patients have entered the progressive stage of MS (secondary progressive, SPMS), therapeutic options are limited to symptomatic treatments and rehabilitation. In addition, 10-20% of patients experience unremitting disease progression (primary progressive MS, or PPMS). The limited research focusing on Progressive MS (PMS) and the lack of ecological validity highlight the need for a bolder approach that combines more than one intervention intending to produce synergistic effects. The primary aim is to test the effectiveness of combining a home-based Digital Telerehabilitation program with in-hospital rehabilitation on mobility against in-hospital rehabilitation alone.",[28],[165,166,167,168,169],"Balance","Dual Task","Cognitive Function","Digital Telemedicine","Wearables","NOT_YET_RECRUITING","2024-06-26",{"date":173,"type":41},"2024-07-03",{"date":175,"type":21},"2024-06-30",{"date":40,"type":21},{"name":178,"class":124},"Universita di Verona",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":132,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":125},"100496168","phase-2-nicotinamide-riboside-supplementation-in-progressive-multiple-sclerosis-100496168","NCT05740722","Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis","Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis: A Randomised Controlled Trial: The NORSEMAN Study","Norseman","Inclusion Criteria:\n\n* A diagnosis of progressive MS (secondary; SPMS or primary; PPMS) according to the 2013 revisions of clinical course of multiple sclerosis and the 2017 revisions of the McDonald criteria.\n* Aged 18-65 years.\n* EDSS 3-6.5\n* Able to perform T25FW test\n* The participant must have documented evidence of disability progression observed during the 24 months before screening.\n* With or without a stable disease modifying therapy during the last three months.\n* Written informed consent for study participation.\n\nExclusion Criteria:\n\n* A diagnosis of relapsing MS according to the revisions of the McDonald criteria\n* Neoplastic disease at baseline\n* Previous history of malignant melanoma or breast cancer\n* Stable phase of a progressive disease course\n* Pregnancy or lactating female patients\n* Dementia or other neurodegenerative disorder at baseline visit\n* Comorbidity (psychiatric or somatic) that precludes study participation\n* Use of high dose vitamin B3 supplementation within 30 days of enrolment\n* Genetically confirmed mitochondrial disease or metabolic disorder",{"count":188,"type":21},300,[25],"The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis.\n\nThe main question it aims to answer is:\n\n• Does NR delay disability progression in progressive multiple sclerosis?\n\nParticipants will be treated with NR or placebo for 30 months,",[33,28],[193],"nicotinamid riboside","2024-01-10",{"date":196,"type":41},"2024-01-11",{"date":198,"type":41},"2023-05-03",{"date":200,"type":21},"2027-12-30",{"name":202,"class":124},"Haukeland University Hospital"]